A Randomized Pilot Trial to Test the Addition of Montanide and Polyiclc to Autologous Oxidized Tumor Cell Lysate Vaccine in Combination With Gmcsf in Primary Advanced Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

This is a randomized pilot trial to test the addition of 2 investigational agents, Montanide and poly-ICLC (a TLR3 agonist) to a backbone of autologous oxidized tumor cell lysate vaccine (OC-L) administered with GMCSF in subjects with primary epithelial ovarian, fallopian tube, or primary peritoneal cancer.

开始日期2015-05-01

申办/合作机构

Abramson Cancer Center

100 项与 Oxidized tumor cell lysate vaccine(University of Pennsylvania) 相关的临床结果

登录后查看更多信息

100 项与 Oxidized tumor cell lysate vaccine(University of Pennsylvania) 相关的转化医学

登录后查看更多信息

100 项与 Oxidized tumor cell lysate vaccine(University of Pennsylvania) 相关的专利（医药）

登录后查看更多信息

项与 Oxidized tumor cell lysate vaccine(University of Pennsylvania) 相关的文献（医药）

2023-02-01·Journal of Cancer Research and Clinical Oncology

The therapeutic effect of an autologous and allogenic mixed glioma cell lysate vaccine in a rat model

Article

作者: Zeng, Shan ; He, Haiping ; Wang, Ping ; Peng, Lilei ; Ming, Yang ; Cen, Yulin ; Lu, Xiaofei ; Zeng, Xu ; Li, Xinlong ; Zhong, Chuanhong ; Chen, Ligang

PURPOSETumor immunotherapy has the advantages of high specificity, minimal damage to the patient's body, and a long-lasting anti-tumor effect. However, due to the existence of immune escape phenomenon, the effect of anti-tumor immunotherapy is still poor. Therefore, a cancer vaccine that reverses tumor-associated immunosuppression is a very promising approach for research and treatment.METHODSVaccines were prepared using autologous and allogeneic tumor cells and their lysates to syngeneic tumor cell lysates as immunogens. The glioma cell proliferation, apoptosis and the secretion level of MCP-2, IFN-γ were detected to evaluate the efficacy of this treatment against glioma in vitro. In addition, a rat glioma model was established to investigate the anti-tumor effect in vivo, and evaluated its efficacy by observing the changes of CD4 + T cells, CD8 + T cells, NK cells, and the level of IL-2 and IL-10 in peripheral blood before and after treatment.RESULTSThe C6 + 9L glioma cell lysate vaccine (C6 + 9L-CL) not only inhibited the proliferation of glioma cells and promoted their apoptosis in vitro, but also significantly inhibited the tumor growth in vivo and improved the survival time of rats. In addition, the C6 + 9L-CL vaccine enhanced the anti-tumor immune response by promoting the secretion of T cell chemokines MCP-2, IFN-γ and IL-2, and by stimulating the proliferation of T cells and NK cells in peripheral blood and glioma tissues.CONCLUSIONOur findings demonstrate the inhibitory effect of molecular mimic vaccines on glioma and provided a theoretical basis for molecular mimic hybrid vaccines as a potential therapeutic approach.

2021-07-01·Translational Lung Cancer Research2区 · 医学

Randomized phase II trial of a first-in-human cancer cell lysate vaccine in patients with thoracic malignancies

2区 · 医学

Article

作者: Hong, Julie A ; Lee, Sunmin ; Yuno, Akira ; Warga, Cheryl L ; Trepel, Jane B ; Zhang, Mary ; Ripley, R Taylor ; Lee, Min-Jung ; Kunst, Tricia F ; Schrump, David S ; Gnjatic, Sacha ; Hoang, Chuong D ; Bond, Colleen D ; Miettinen, Markku ; Kenney, Cara M ; Yeray, Javier

BACKGROUNDAlthough most malignancies express cancer-testis antigens (CTA), immune responses to these proteins are limited in thoracic oncology patients. This trial was undertaken to examine if a cancer cell lysate vaccine could induce immunity to CTA, and to ascertain if metronomic cyclophosphamide and celecoxib enhances vaccine-induced immune responses.METHODSEleven patients with primary thoracic malignancies and 10 patients with extrathoracic neoplasms metastatic to the chest rendered NED by conventional therapies were randomized to receive H1299 lung cancer cell lysates (10 mg protein/vaccine) with Iscomatrix™ adjuvant via deep intradermal injection q 4 weeks ×6 with or without daily oral metronomic cyclophosphamide/celecoxib. The primary endpoint was serologic response to purified CTA assessed 1 month after the 6^th vaccination. Secondary endpoints included assessment of the effects of cyclophosphamide and celecoxib on frequency and magnitude of vaccine-induced immune responses to CTA. Exploratory endpoints included evaluation of the effects of the vaccine regimens on peripheral immune subsets. Standard of care imaging studies were obtained at baseline and 1 month after the 3^rd and 6^th vaccinations.RESULTSAll patients exhibited local and systemic inflammatory responses lasting 72-96 hours following vaccinations. There were no dose limiting treatment related toxicities. Fourteen patients (67%) completed all six vaccinations. Eight of 14 patients (57%) exhibited serologic responses to NY-ESO-1. One patient developed antibodies to GAGE7; several patients exhibited reactivity to XAGE and MAGE-C2. Vaccine therapy decreased the percent of Tregs (P=0.0068), PD-1 expression on Tregs (P=0.0027), PD-L1 expression on CD14⁺ monocytes (P=0.0089), PD-L1 expression on classical monocytes (P=0.016), and PD-L1 expression on intermediate monocytes (P=0.0031). Cyclophosphamide/celecoxib did not appear to increase immune responses or enhance vaccine-induced alterations in peripheral immune subsets.CONCLUSIONSH1299 lysate vaccines with Iscomatrix™ induce immune responses to CTA and modulate peripheral immune subsets in a manner that may enhance antitumor immunity in patients with thoracic malignancies.

2018-08-01·Biomedicine & Pharmacotherapy2区 · 医学

Anti-tumor effects of propranolol: Adjuvant activity on a transplanted murine breast cancer model

2区 · 医学

Article

作者: Mehdi Mahdavi ; Ahmad Shirkhani ; Somayeh Ashrafi ; Reza Shapouri

Propranolol (Pro), a non-specific β-adrenergic blocking drug, competitively prevents the binding of catecholamines to receptors and suppresses cancer cells. The anti-tumor activity of propranolol has been proved in different kinds of cancers. In this study, we assessed the adjuvant activity of propranolol combined with a tumor vaccine model on the immunological parameters of breast tumor-bearing mice. Breast tumor pieces were implanted into the flank of inbred BALB/C female mice from stock mice. Tumor-bearing mice were treated with tumor antigen lysate vaccine and propranolol/Vaccine (Pro/Vac) combination (as treatment groups), propranolol and PBS (as control groups) for 5 consecutive days, every 12 h. Moreover, all experimental groups received vaccine for three times with one-week interval via s.c injection. After immunization courses, spleens of tumor-bearing mice were removed and dissected, cell suspension was stimulated in vitro, and the cytokine levels in supernatant of splenocytes were measured via commercial ELISA kits. Compared with the vaccine group, immunization with tumor lysate in combination with propranolol significantly increased IL-2, IL-4, IL-12, IL-17, and IFN-γ cytokines. Considering the suppression of tumor growth, propranolol seems to be a potent immunomodulator capable of inducing cellular immune responses against breast cancer.

100 项与 Oxidized tumor cell lysate vaccine(University of Pennsylvania) 相关的药物交易

登录后查看更多信息